Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

YUMANITY THERAPEUTICS, INC.

(YMTX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

YUMANITY THERAPEUTICS, INC. : Change in Directors or Principal Officers, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

08/16/2021 | 07:30am EDT

Item 5.02 Departure of Directors or Certain Officers; Election of Directors;

Appointment of Certain Officers; Compensatory Arrangements of Certain

Officers.

On August 16, 2021, Yumanity Therapeutics, Inc. (the "Company") announced the appointment of Michael D. Wyzga as Senior Vice President and Chief Financial Officer of the Company, effective on August 16, 2021. Mr. Wyzga was also appointed as the Company's principal financial officer, effective August 16, 2021.

Mr. Wyzga, age 32, joins the Company from Needham & Company, where he most recently served as Healthcare Investment Banking Vice President and previously served as a Healthcare Investment Banking Associate from June 2014 to August 2021. Prior to that, he served as a Healthcare Corporate and Investment Banking Analyst at CitiGroup, Inc. from 2011 to 2013. Mr. Wyzga received a B.A. in Finance from Lehigh University and an M.B.A. from the Cornell University Johnson School of Business.

In connection with Mr. Wyzga's election as Senior Vice President and Chief Financial Officer, the Company entered into an employment offer letter (the "Wyzga Agreement") which provides for, among other things: (i) annual base salary of $350,000; (ii) target annual incentive compensation up to 40% of his annual base salary; and (iii) severance and change in control benefits following termination of employment as described below, subject to Mr. Wyzga's execution and non-revocation of a separation agreement in a form satisfactory to the Company that shall contain, among other things, a full and general release of claims in favor of the Company, standard post-employment obligations and, as applicable, a noncompetition covenant that restricts certain competitive activities for a specified period of time and compliance with Mr. Wyzga's Employee Confidentiality, Non-Competition, Non-Solicitation and Intellectual Property Agreement (which he is required to sign as a condition of employment). If Mr. Wyzga is terminated without cause or he resigns his employment for good reason (as "cause" and "good reason" are defined in the Wyzga Agreement), he will be entitled to (i) nine months of severance based on his then-annual base salary, and (ii) the employer portion of the COBRA premiums for health benefit coverage for up to nine months to the extent permitted by and consistent with COBRA and other applicable laws. In the event that such termination without cause or resignation for good reason occurs within three months prior to or twelve months following a change of control (as defined in the Wyzga Agreement), then, in lieu of the severance benefits specified in the preceding sentence, Mr. Wyzga will be entitled to receive (i) nine months of severance based on his then-annual base salary, (ii) full vesting of any granted equity awards then held by Mr. Wyzga, (iii) an extension of the deadline to exercise any vested stock options to nine months following the date of termination or, if earlier, the normal expiration date of the options, and (iv) the employer portion of the COBRA premiums for health benefit coverage for up to nine months to the extent permitted by and consistent with COBRA and other applicable laws.

--------------------------------------------------------------------------------

Mr. Wyzga also will be eligible to participate in the Company's sponsored benefits provided to other Company employees of similar rank and tenure, subject to the terms of and conditions of such policies and programs. Mr. Wyzga will be granted a signing bonus in the form of a cash bonus of $25,000, to be paid on the first payroll date following the one year anniversary of the commencement of his employment with the Company, provided that he remains employed by the Company on the date of payment. In addition, Mr. Wyzga will be granted an option to purchase 65,000 shares of the Company's common stock, which will vest over four years, with 25% of the shares vesting on the one-year anniversary of the commencement of Mr. Wyzga's employment and the remaining shares vesting in thirty-six equal monthly installments thereafter, subject to continued employment through the applicable vesting date. The option will be granted as an inducement material to Mr. Wyzga entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

The foregoing summary of the Wyzga Agreement is qualified in its entirety by reference to the full Wyzga Agreement filed herewith as Exhibit 10.1 and incorporated by reference herein.

The Company entered into an indemnification agreement with Mr. Wyzga in connection with his employment, which is in substantially the same form as that entered into with the other executive officers of the Company and is incorporated herein by reference.

Item 7.01. Regulation FD Disclosure.

On August 16, 2021, the Company issued a press release titled "Yumanity Therapeutics, Inc. Appoints Michael D. Wyzga as Chief Financial Officer and Announces Inducement Grants". A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01 and Exhibit 99.1 attached hereto are intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits



(d) Exhibits.



Exhibit
  No.                                      Document

10.1          Employment Offer Letter by and between Yumanity Therapeutics, Inc.
            and Michael D. Wyzga, dated July 12, 2021 (redacted).

99.1          Press Release of Yumanity Therapeutics, Inc. dated August 16, 2021.


104         The cover page from this Current Report on Form 8-K, formatted in
            Inline XBRL.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about YUMANITY THERAPEUTICS, INC.
10/14Yumanity Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
09/09YUMANITY THERAPEUTICS : Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
AQ
09/09YUMANITY THERAPEUTICS : to Present at the H.C. Wainwright 23rd Global Investment Conferenc..
AQ
08/16Yumanity Therapeutics, Inc. Announces Appointment of Michael D. Wyzga as Chief Financia..
CI
08/16YUMANITY THERAPEUTICS : Appoints Michael D. Wyzga as Chief Financial Officer and Announces..
PU
08/16YUMANITY THERAPEUTICS, INC. : Change in Directors or Principal Officers, Regulation FD Dis..
AQ
08/16Yumanity Therapeutics, Inc. Announces Executive Changes
CI
08/16Yumanity Therapeutics Appoints Michael D. Wyzga as Chief Financial Officer and Announce..
GL
08/12YUMANITY : Q2 Earnings Snapshot
AQ
08/12YUMANITY THERAPEUTICS : Reports Second Quarter 2021 Financial Results and Recent Corporate..
PU
More news
Analyst Recommendations on YUMANITY THERAPEUTICS, INC.
More recommendations